RL71

RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks[1].

Product Specifications

CAS Number

[1195795-93-7]

UNSPSC

12352005

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rl71.html

Purity

97.44

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1/C(CN(C/C1=C\C2=CC(OC)=C(C(OC)=C2)OC)C)=C/C3=CC(OC)=C(C(OC)=C3)OC

Molecular Formula

C26H31NO7

Molecular Weight

469.53

References & Citations

[1]Yadav B, et al. RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells. Int J Oncol. 2012 Sep;41 (3) :1119-27.